Three of the most important issues facing the biopharmaceutical community today are the need for increased transparency, the current global economy, and the changing methods used to develop drugs and to assess their efficacy and safety. This meeting will address all of these challenges and explain ways to overcome them through effective global collaboration:

- Find out the changes within the Canadian and global regulatory environments
- Describe the pharmacovigilance and risk assessment of therapeutics development
- Learn the latest domestic and international processes in conducting clinical trials
- Maximize the ongoing monitoring of therapeutics
- Learn the value of increased transparency

Pre-meeting Tutorials: November 2, 2009
Meeting: November 3-4, 2009
The Westin Ottawa Hotel
Ottawa, Ontario, Canada

Member Early-bird Rate — Register by October 15 and SAVE $190

DIA’S 7TH CANADIAN ANNUAL MEETING
“Time to Act”

Three of the most important issues facing the biopharmaceutical community today are the need for increased transparency, the current global economy, and the changing methods used to develop drugs and to assess their efficacy and safety. This meeting will address all of these challenges and explain ways to overcome them through effective global collaboration:

- Find out the changes within the Canadian and global regulatory environments
- Describe the pharmacovigilance and risk assessment of therapeutics development
- Learn the latest domestic and international processes in conducting clinical trials
- Maximize the ongoing monitoring of therapeutics
- Learn the value of increased transparency

Pre-Meeting Tutorials: November 2, 2009, 1:30-5:00 pm
Risk Communication
Tutorial registration is separate; please indicate if you plan to attend a tutorial.

WHO SHOULD ATTEND
This program will benefit individuals involved in:

- Regulatory affairs
- Policy/pharmacoeconomics
- Clinical research
- Drug safety/pharmacovigilance
- Drug development
- Quality assurance
- Reimbursement
- Academia

CONTACT INFORMATION
Meeting: Joanne Wallace, Phone +1-215-442-6180 email Joanne.Wallace@diahome.org
Exhibits: Jeff Korn, Phone +1-215-442-6184 email Jeff.Korn@diahome.org
DIA’s 7th Annual Canadian Meeting

Accreditation and Credit Designation

The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. This program is designated for 8.75 contact hours or .875 continuing education units (CEUs). 286-000-09-030-L04-P.

The Drug Information Association (DIA) has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 8405 Greensboro Drive, Suite 800, McLean, VA 22102. DIA is authorized by IACET to offer 0.9 CEUs for this program.

- Tutorial is approved for 0.3 IACET CEUs.
- The opening remarks will not offer credit.
- The opening plenary session will offer 1.25 pharmacy contact hours or .125 continuing education units (CEUs) and 0.1 IACET CEUs.

The following tracks will offer these additional continuing education credits:

**Tuesday, November 3, 1:30-3:00 PM**
- Session 1 – Track 1: 1.5 pharmacy contact hours or .15 continuing education units (CEUs) and 0.2 IACET CEUs
- Session 1 – Track 2: 0.2 IACET CEUs
- Session 1 – Track 3: 0.2 IACET CEUs

**Tuesday, November 3, 3:30-5:00 PM**
- Session 2 – Track 1: 1.5 AMA PRA Category 1 Credit(s)™; 1.5 pharmacy contact hours or .15 continuing education units (CEUs); 0.2 IACET CEUs
- Session 2 – Track 2: 1.5 pharmacy contact hours or .15 continuing education units (CEUs); 0.2 IACET CEUs
- Session 2 – Track 3: 1.5 AMA PRA Category 1 Credit(s)™; 0.2 IACET CEUs

**Wednesday, November 4, 8:30-10:00 AM**
- Session 3 – Track 1: 1.5 pharmacy contact hours or .15 continuing education units (CEUs) and 0.2 IACET CEUs
- Session 3 – Track 2: 1.5 pharmacy contact hours or .15 continuing education units (CEUs) and 0.2 IACET CEUs
- Session 3 – Track 3: 0.2 IACET CEUs

**Wednesday, November 4, 10:30 AM-12:00 PM**
- Session 4 – Track 1: 0.2 IACET CEUs
- Session 4 – Track 2: 1.5 pharmacy contact hours or .15 continuing education units (CEUs); 0.2 IACET CEUs
- Session 4 – Track 3: 0.2 IACET CEUs

To receive a statement of credit, complete the on-line credit request process through My Transcript at www.diahome.org. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on Thursday, November 5, 2009.

Disclosure Policy

It is Drug Information Association policy that all faculty participating in continuing education activities must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosure will be included in the course materials.

Learning Objectives: At the conclusion of this meeting, participants should be able to:

- Recognize the changes that are occurring within the Canadian and global regulatory environments;
- Discuss new directions being taken to improve pharmacovigilance and risk assessment of pharmaceutical products;
- Describe the impact and implications of new domestic and international processes in conducting clinical trials;
- Identify the roles of multiple stakeholders (industry, regulators, health-care providers and patients) for effective medical product risk management and minimization;
- Discuss the value of increased transparency and the risks this could pose in the decision-making process;
- Compare the Canadian perspective to various international issues.
GROUP DISCOUNTS* Register 3 individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.

To take advantage of this offer, please make a copy of this registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.

TRAVEL AND HOTEL
The most convenient airport is Ottawa International Airport and attendees should make airline reservations as early as possible to ensure availability. The Westin Ottawa Hotel is holding a block of rooms at the reduced rate below until October 9, 2009, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

Single $219 CN Double $269 CN

Please contact the Westin Ottawa Hotel by telephone at +1-800-WESTIN or 1-613-560-7000. The hotel is located at 11 Colonel By Drive, Ottawa, Ontario, Canada K1N 9H4.

Monday, November 2, 2009 (Pre-meeting Event Only)

11:00 AM-1:30 PM Tutorial Registration

12:00-5:00 PM Exhibitor Set-up and Registration

1:30-5:00 PM Tutorial

Tutorial:
Risk Communication

INSTRUCTOR:
Lisa Dolovich, BScPhm, PharmD, MSc
Research Director and Associate Professor, Department of Family Medicine, McMaster University Scientist and Associate Director, Centre for Evaluation and Medicines

Ensuring the safe and effective use of medical products is becoming increasingly complex. Risk communication is an integral and vital element of any risk management strategy. Often this involves communicating emerging or identified safety risks related to pharmaceutical drug products to both providers and patients alike. Conveying complex information in a balanced, clear, quick and efficient manner is critical to effective communication. Challenges faced with this evolving discipline include gaining an understanding of the effectiveness of the communication when directed to providers and patients since the requirements are inherently different. How well does this communication work? What factors are the most important? Evaluating the effectiveness of risk communication is necessary to ensure the efficiency and quality of the communications.

Tutorial Learning Objectives
At the conclusion of this tutorial, participants should be able to:
• Recognize the different factors which influence effective risk communications for providers and patients
• Identify best practices and factors which are important for effective risk communications directed to patients
• Recognize the shared responsibility of multiple stakeholders in effective risk communications (regulator, manufacturer, health care provider)

Tutorial Target Audience
This tutorial is designed for individuals involved in regulatory affairs, compliance and labeling, medical information, quality assurance/quality control, clinical research, risk management, drug safety/pharmacovigilance, academia.

4:00-6:00 PM Meeting Registration
Tuesday, November 3, 2009

7:30-8:30 AM  Registration and Continental Breakfast

8:30-10:15 AM  OPENING PLENARY SESSION

OPENING REMARKS – DIA
Judith Glennie, PharmD, MSc, FCSPH, Director, Submissions/Postmarketing Effectiveness Research (PMER), Planning Medical and Government Affairs, Janssen-Ortho, Inc., Canada; DIA Board of Directors

WELCOME
David Krakovsky, BScPhm, PharmD, Director, Medical Safety, Information and Governance, GlaxoSmithKline, Inc., Canada
Agnes V. Klein, MD, DrPH, Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, BGTD, HPFB, Health Canada

KEYNOTE ADDRESSES:

8:40-9:40 AM  THE FUTURE OF HEALTH CARE AND PHARMACEUTICAL DEVELOPMENT
Paul Crotty  General Manager, IMS Canada

9:45-10:15 AM  THE NEED TO TAKE ON THE CHALLENGE OF ALIGNMENT OF PHARMA WITH PAYOR NEEDS
Bob Nakagawa  Assistant Deputy Minister, Pharmaceutical Services, British Columbia Ministry of Health Services

10:15-10:45 AM  Refreshment Break in the Exhibit Hall (Hall opens at 9:30 AM)

10:45 AM-12:15 PM  OPENING PLENARY SESSION continued

TRANSPARENCY – WHAT IS DESIRABLE? HOW FAR?

- TRANSPARENCY: CHALLENGES AND OPPORTUNITIES FOR THE CANADIAN REGULATOR
  Supriya Sharma, MD, MPH, FRCPC, Director General, Therapeutic Products Directorate, Health Canada

- CLINICAL TRIAL TRANSPARENCY – INDUSTRY PERSPECTIVE
  Cathie Schumaker, Executive Director, FDA Liaison Office, Global Regulatory Policy, Intelligence and Labeling, AstraZeneca US

- LEGAL IMPLICATIONS AND INCREASED RISK
  Jeffrey S. Graham, Partner, Borden Ladner Gervais, LLP

12:15-1:30 PM  Luncheon in the Exhibit Hall

TRACK CHAIRS

<table>
<thead>
<tr>
<th>Track 1: Clinical Development</th>
<th>Track 2: Safety/Pharmacovigilance</th>
<th>Track 3: Regulatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diane Colizza, BSc, MBA</td>
<td>Sarah Frise, PhD</td>
<td>Anne Tomalin</td>
</tr>
<tr>
<td>ICRO Group Head, General Medicines, Clinical Group, Novartis Pharmaceuticals, Canada, Inc.</td>
<td>Director, Patient Safety and Medical Information, AstraZeneca, Canada, Inc.</td>
<td>President, CanReg, Inc. Canada</td>
</tr>
<tr>
<td>Judith Atkins, PhD</td>
<td>Kimby Barton, MSc</td>
<td>Karen Feltmate</td>
</tr>
<tr>
<td>Principal Consultant, PAREXEL Consulting, Canada</td>
<td>Interim Director in BCANS of TPD, Health Canada</td>
<td>Vice President, Operations Business Services and Regulatory Affairs, AstraZeneca, Canada, Inc.</td>
</tr>
<tr>
<td>Nigel Rawson, PhD</td>
<td></td>
<td>Agnes V. Klein, MD, DrPH</td>
</tr>
<tr>
<td>Pharmacoepidemiologist, GlaxoSmithKline, Inc. Canada</td>
<td></td>
<td>Director, Center for Evaluation of Radio-pharmaceuticals and Biotherapeutics, BGTD, HPFB, Health Canada</td>
</tr>
</tbody>
</table>
The safety and well-being of patients is the first consideration in clinical trials and the protection of human subjects is a responsibility shared by all stakeholders in clinical development. The Research Ethics Board review of the protocol, informed consent form, and investigator qualifications is a key step.

In this session, the role of the REBs in the protection of human subjects, particularly in special or vulnerable populations, will be explored.

Speakers

**Role of REBs in the Protection of Human Subjects: Special Populations**

**Session Chair**
Diane Colizza, BSc, MBA
ICRO Group Head, General Medicines, Clinical Group, Novartis Pharmaceuticals, Canada, Inc.

**Speakers**

- **An Update on the Development of Voluntary Canadian REB Standards**
  Norman Viner, MD
  Manager, Clinical Trials Division, Health Canada

- **Ethical and Regulatory Considerations in REB Review of Research with Special and Vulnerable Populations**
  Jack Corman
  President, IRB Services

- **REB Academic Standards**
  Ronald Heslegrave, PhD
  Chair, Research Ethics Board, University Health Network

---

**Evolving Safety Science**

**Session Chair**
Kimby Barton, MSc
Interim Director in BCANs of TPD
Health Canada

The science of safety is rapidly evolving. This science combines the growing understanding of disease origins, pharmacogenomics with new methods of detecting signals, mining and analyzing data. This evolving science is enabling researchers to develop and test hypotheses regarding the association between specific products and health outcomes. This session will discuss some of the traditional tools and newer tools used to detect signals and analyze benefit and risk.

**Speakers**

- **Overview of Traditional Tools and Techniques Used in Signal Detection, Risk Assessment (Pharmacovigilance Databases, Data Mining)**
  Yola Moride, PhD, FISPE
  Associate Professor, Faculty of Pharmacy, University of Montreal

- **Developing Trends in the Application of Models to Benefit-Risk Assessment**
  Rick Hermann, MD, MPH
  Director, Clinical Research, Epidemiology, AstraZeneca Pharmaceuticals R&D

- **Tools for Risk: Benefit Quantification and Assessment**
  Lucye MJ Galand, DVM
  Manager, Scientific Section 1
  Health Canada

---

**Developments in Biosimilars in Canada, US, Europe, ICH, and WHO**

**Session Chair**
Kwasi Nyarko, MSc, PhD
Unit Manager, Special Projects, Office of Policy and International Collaboration, Division, BGTD, HPFB, Health Canada

This session will provide an update on developments related to subsequent entry biologics/biosimilars in Canada, the United States, Europe, the ICH and WHO. In addition, a case study will be presented in terms of establishing similarity of structure between several biologic products, including associated preclinical/clinical similarities/differences.

**Speakers**

- **Developments in Biosimilars in Canada, US, Europe, ICH and WHO**
  Kwasi Nyarko, MSc, PhD
  Unit Manager, Special Projects, Office of Policy and International Collaboration, Division, BGTD, HPFB, Health Canada

- **Subsequent Entry Biologics in Canada: An Innovative Industry Perspective**
  Karen Burke, PhD
  Director, Regulatory Affairs, Amgen Canada, Inc.

- **The Intersection of Complex Drugs and Biologics: Challenges in Characterization of Similarity**
  J. Michael Nicholas, PhD, Postdoctoral Fellow
  Senior Director, Strategic Regulatory Affairs and Postmarketing Labeling/Compliance, Teva Neuroscience

---

3:00-3:30 PM Refreshment Break in the Exhibit Hall
PARALLEL TRACKS – SESSION 2

SESSION 2 – TRACK 1

PHARMACOGENOMICS

Session Chair
Agnes V. Klein, MD, DrPH
Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, BGTD, HPFB, Health Canada

Pharmacogenomics is no longer a new brand to the art and science of drug development. Despite this, the uptake of pharmacogenomics is still evolving and its proper place is in the process of being better defined. Many of the issues that have given rise to concerns such as the use of biological materials stored for future research and the need to develop biomarkers in order to optimize the science are well on their way to being resolved, thanks to the impetus provided by Critical Path Initiative of the FDA.

It is clear that the initiatives that have spun off the Critical Path Initiative have increased the profile of research conducted to identify, qualify and validate analytically and clinically a number of biomarkers. Nonetheless, pharmacogenomics remains a new but rapidly evolving science with implications in a number of areas that range from discovery to clinical and regulatory. Pharmacogenomics holds the promise to improve both the efficacy and the safety of drug products. This session will provide three perspectives on what is needed to maintain and continue advancing the field.

Speakers

REGULATORY PERSPECTIVE
Brian Foster, PhD
Senior Science Advisor, Therapeutic Products Directorate, Health Canada

RESEARCH PERSPECTIVE
Michael S. Phillips, PhD
Canada Research Chair in Translational Pharmacogenomics, Director of Pharmacogenomics, Genome Quebec

IMPACT OF PHARMACOGENOMICS ON CLINICAL TRIALS
Carolyn Finkle, MSc
Senior Director, International Regulatory Affairs MedImmune

SESSION 2 – TRACK 2

PHARMACOVIGILANCE OPERATIONS

Session Chair
Heather Sutcliffe
Director, Marketed Health Products Safety and Effectiveness Information Bureau, Health Canada

With changes to the science of pharmacovigilance come necessary changes to associated operations. This session will provide information from Health Canada on the electronic submission of case reports, new processes regarding pharmacovigilance inspections and the latest guidance on responsibilities for ADR reporting.

Speakers

ELECTRONIC REPORTING OF ADVERSE REACTION REPORTS TO CANADA VIGILANCE BY INDUSTRY
Michel Trottier, BScPhm, RPEBC, ACPR, RPh A
Canada Vigilance Project Lead – Adverse Reactions Electronic Reporting, Health Canada

POSTMARKET REPORTING COMPLIANCE INSPECTIONS
Sophie Lafrance
HPFB Inspectorate, Health Canada

GUIDANCE DOCUMENT FOR INDUSTRY -- REPORTING OF ADVERSE REACTIONS TO MARKETED HEALTH PRODUCTS
Jennifer Lo
Head of Operations Unit – Case Report, Database and Terminology Section, Health Canada

SESSION 2 – TRACK 3

PATIENT ACCESS: WHAT IS YOUR ROLE IN FACILITATING PATIENT ACCESS?

Session Chair
Karen Feltmate
Vice President, Operations Business Services and Regulatory Affairs, AstraZeneca, Canada, Inc.

This session will feature five perspectives in delivering medicines to patients. Knowledgeable speakers representing the following organizations will introduce their role in this process and, through lively panel discussion, will respond to leading questions. The five perspectives are from Clinical Trials, Health Canada, CDR/Provincial Formularies, PMPRB and last but not least, Patients.

PANEL DISCUSSION

Speakers

CLINICAL TRIALS
Karen Arts
Director, Business Development, Ontario Institute for Cancer Research

HEALTH CANADA
Brigette Zirger, MSc
Director, Bureau of Policy, Science and International Programs, Therapeutic Products Directorate, Health Canada

CDR/PROVINCIAL FORMULARIES
George Wyatt
Managing Director, Wyatt Health Management Consulting, Inc.

CANADA’S PATENTED MEDICINE PRICES REVIEW BOARD - MOVING FORWARD WITH THE IMPLEMENTATION OF ITS NEW EXCESSIVE PRICE GUIDELINES
Barbara Ouellet
Executive Director, Patented Medicine Prices Review Board

PATIENT PERSPECTIVE
Kathy Kovacs Burns
Best Medicines Coalition

5:00-6:00 PM Networking Reception in Exhibit Hall
Ideally investigator sites should always be ‘audit-ready’. In reality, a wealth of activities and demands at the site, many with short deadlines, make it difficult to achieve documentation-readiness at all times. This session will explore recent trends in findings from site audits and inspections and approaches that can be taken by investigator sites to facilitate preparations and meet or surpass the requirements.

### Speakers

**Recent Trends and Findings**
- Ann-Merie O’Halloran, PhD
  - Manager, Clinical Capabilities and Compliance Office, Novartis Pharmaceuticals, Canada, Inc.

**Clinical Trial Inspections: Recent Trends and Findings**
- Stephanie Reid
  - Manager, Good Clinical Practices Compliance Unit, Health Canada

**Get Your Site Together**
- Deborah D’Urzo, MSc
  - Research Director, Primary Care Lung Clinic, Canada

Both Europe and the United States implemented Patient Risk Management Planning into their regulatory framework in 2005. As such, they have had a few years to work with these requirements. Health Canada is currently in the process of modernization of Canadian legislation and regulations with plans to formally require Risk Management plans for certain products. This session will provide an update from each regulator on their current status with respect to requirements for Risk Management Plans, some of their learnings and some idea of what the future might hold in this area.

### Speakers

**EMEA Perspective**
- Stella Blackburn, MSc
  - EMEA Risk Management Coordinator, Pharmacovigilance and Postauthorization Safety and Efficacy of Medicines Sector, European Medicines Agency, European Union

**FDA Perspective**
- Barton Cobert, MD
  - President, BLCMD Associates LLC

**Health Canada Perspective**
- Kimby Barton, MSc
  - Interim Director in BCANs of TPD
  - Health Canada

Many industries have leveraged technology to revolutionize their business models and reshape their ability to interact with customers. With the advent of technologies like eCTD, XML labelling and new media, the life sciences industry is in the early stages of a major transformation. This transformation will have far reaching consequences and benefits, and will help reshape the way health care is managed.

### Speakers

**The Outcome of the Hybrid eCTD Program and the Impact It Will Have on the HPFB**
- Vianney Caron
  - Project Lead, Therapeutic Products Directorate eReview, Health Canada

**Electronic Labelling: A Comparison of the FDA, EMEA, and Health Canada Approaches**
- Keith Thomas
  - Product Strategist
  - Infrastructures for Information, Inc. Canada

**The Power of New Media and Its Use in Health Care**
- Joel Alleyne
  - President, Alleyne, Inc.; Practitioner in Residence, Knowledge Media Design Institute, University of Toronto; Instructor, Faculty of Information and Faculty of Medicine, University of Toronto, Canada
Clinical trials involve a plethora of ethical issues. The issues vary based on the target population, location, indication and study design. This session explores various ethical issues in the conduct of clinical trials, not only in Canada, but also globally.

**Speakers**

**ETHICS OF PLACEBO USE IN CLINICAL TRIALS**  
Professor Kathleen Glass  
Clinical Trials Research, McGill University

**PATIENT COMPENSATION**  
Speaker has been invited

**REGULATORS PERSPECTIVE**  
Agnes V. Klein, MD, DrPH  
Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, BGTD, HPFB, Health Canada  
Norman Viner, MD  
Manager, Clinical Trials Division, Health Canada

The aim of this session is to compare and contrast three networks created for drug safety and effectiveness research. Speakers will be asked to address the purpose of each network, where they are today, and their future directions. Opportunities for international collaboration will also be addressed.

**Speakers**

**DSEN (DRUG SAFETY EFFECTIVENESS NETWORK) CANADA**  
Diane Forbes  
Associate Director for the Drug Safety and Effectiveness Network, Canadian Institutes of Health Research

**SENTINEL INITIATIVE: USA (VIA AUDIO COMMUNICATIONS)**  
Judith Racossin, MD, MPH  
Sentinel Initiative Scientific Lead, Associate Director, Medical Product Safety Programs, Office of the Commissioner, FDA

**ENCEPP – EUROPE (VIA AUDIO COMMUNICATIONS)**  
Henry Fitt  
Specialized Group Leader ONC/CVS, European Medicines Agency, European Union

This session will explore how orphan drugs are developed, regulated, and accessed by patients in Canada, including a comparison to the US and Europe. The industry's perspective, the regulator's perspective and the patient's perspective will be considered.

**Speakers**

**ISSUES IN DEVELOPING ORPHAN DRUGS FOR RARE DISEASES**  
Dayton Reardon, PhD  
Vice President, Regulatory Affairs, Eleos Inc., USA

**ORPHAN DRUG POLICY IN THE US AND EUROPE**  
John J. McCormick, MD  
Independent Consultant, McCormick Consultation, LLC; Former Head of the Orphan Drug Division of FDA, USA

**ACCESSING DRUGS FOR RARE DISEASES IN CANADA**  
Elizabeth Fowler  
Partner, World Health Advocacy; Board Member, Canadian Organization for Rare Disorders

More and more often, the clinical use of product reflects the current published Therapeutic Guidelines and literature (ahead of a monograph revision). Clinical development is advanced using surrogate biomarkers which are not yet validated in regulatory approvals. How can we bring clinical practice closer together with the Regulatory Product Label (Product Monograph)? If and when this is accomplished, does it help, hinder or add any value to the payor review process?

- **OVERVIEW OF CLINICAL GUIDELINE PREPARATION**  
  Antoine Abugaber, President of ABUGABER CANADA Inc., Oncology Management Services

- **INDUSTRY PERSPECTIVE ON THE VALUE/USE OF CLINICAL THERAPEUTIC GUIDELINES**  
  Gerry Jeffcott, Health and Pharmaceutical Policy Consultant

- **REGULATORY PERSPECTIVE ON USE AND CORPORATE GUIDELINES IN REGULATORY DECISIONS**  
  Agnes V. Klein, MD, DrPH, Director, Center for Evaluation of Radiopharmaceuticals and Biotherapeutics, BGTD, HPFB, Health Canada

3:00 PM  
Canadian Annual Meeting Adjourned
DIA’S 7th CANADIAN ANNUAL MEETING
“Time to Act”
Westin Ottawa Hotel, Ottawa
Ontario, Canada
NOVEMBER 2-4, 2009

MEMBER EARLY BIRD
Register by OCTOBER 15, 2009 SAVE $190

Register online or fax this page to +1-215-442-6199

CONTACT & EXHIBIT INFORMATION
Attendees may visit the exhibits during the meeting and during receptions (if applicable).

Meeting information: Contact Joanne Wallace at the DIA office by telephone +1-215-442-6180, fax +1-215-442-6103 or email Joanne.Wallace@diahome.org.

Exhibit information: Contact Jeff Korn, Exhibits Associate, at the DIA office by telephone +1-215-442-6184, fax +1-215-442-6199 or email Jeff.Korn@diahome.org. For exhibit space, please check the box below.

GROUP DISCOUNTS (not available online or on already discounted fees)
Register 3 individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the same time – no exceptions. See page 3 for complete details.

CANCELLATION POLICY: On or before OCTOBER 27, 2009
Administrative fee that will be withheld from refund amount:
Member or Nonmember = $200
Government or Academic or Nonprofit (Member or Nonmember) = $100
Tutorial = $50

Registration Fees
If DIA cannot verify your membership upon receipt of registration form, you will be charged the nonmember fee. Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.

MEMBER EARLY-BIRD OPPORTUNITY
Available on nondiscount member fee only

<table>
<thead>
<tr>
<th></th>
<th>On or before OCT. 15, 2009</th>
<th>After OCT. 15, 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Fee</td>
<td>US $1260 □</td>
<td>US $1450 □</td>
</tr>
<tr>
<td>Nonmember Fee</td>
<td>US $1590 □</td>
<td></td>
</tr>
</tbody>
</table>

To qualify for the early-bird discount, registration form and accompanying payment must be received by the date above. Does not apply to government/academic/nonprofit members.

We are not responsible for any airfare, hotel or other costs incurred by registrants.

REGISTRATION FORM
Do not remove mailing label. Please return this entire page.

Please check the applicable category:
√ Academia  □ Government  □ Industry  □ CSO  □ Student (Call for registration information)

Last Name □ Check if part of group registration □ First Name □ M.I.

Address: As required for postal delivery to your location

City __________________________ State ______ Zip/Postal ______ Country ______

Email __________________________ Required for confirmation

Phone Number ____________________ Required for confirmation

PAYMENT
REGISTER ONLINE AT www.diahome.org or please check payment method:

□ CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

□ CREDIT CARD number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

□ Visa □ MC □ AMEX Expiration Date __________________________

Card # __________________________ Signature __________________________

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.